<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388529</url>
  </required_header>
  <id_info>
    <org_study_id>SPIHF-202</org_study_id>
    <nct_id>NCT02388529</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, randomized, double-blind, placebo-controlled study in patients
      with stable heart failure to evaluate the safety, tolerability, pharmacokinetics, and
      efficacy of multiple ascending doses of Bendavia™ (MTP-131) intravenous infusion.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Assessed up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean peak plasma concentration (Cmax) of MTP-131 (ng/ml) in each cohort</measure>
    <time_frame>Assessed up to Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in echocardiographic LV end-systolic volume (LVESV)</measure>
    <time_frame>Assessed up to Day 33</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days</description>
    <arm_group_label>Intermediate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTP-131</intervention_name>
    <description>MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF ≤45% by 2-D echocardiogram.

          -  Diagnosis of New York Heart Association Class II or III HF for a minimum of 6 months
             prior to the Screening Visit.

          -  HF is considered to be stable, in the judgment of the Principal Investigator and no
             hospitalization related to HF has occurred within the 1 month prior to the Screening
             Visit.

          -  Treatment with appropriate pharmacologic therapy for HF including, but not limited to,
             angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker
             (ARB), and an evidence-based beta blocker for the treatment of HF

          -  Females of child-bearing potential must have a negative serum pregnancy test at the
             Screening Visit.

          -  Written informed consent obtained that strictly adheres to the written guidelines from
             the local Ethical Committee (EC).

        Exclusion Criteria:

          -  Unstable angina pectoris within 1 month before initiation of screening procedures.
             Unstable angina is defined as the occurrence of chest pain more frequently than usual,
             pain at rest or upon minimal exertion, or protracted episodes of pain without any
             discernible trigger, and/or chest pain that persists despite use of vasodilatory
             therapy (e.g., nitroglycerin).

          -  Coronary or peripheral artery revascularization procedure within 2 months prior to the
             Screening Visit.

          -  An acute myocardial infarction within 3 months prior to the Screening Visit.

          -  Supine resting heart rate ≥ 100 beats per minute after 5 minutes rest.

          -  Uncontrolled hypertension defined as a systolic blood pressure (BP) &gt;180 mm Hg or a
             diastolic BP &gt;110 mm Hg on at least 2 consecutive readings.

          -  Requirement for valve or other cardiac surgery (e.g., pericardectomy).

          -  Cardiac surgery or valvuloplasty within 2 month prior to the Screening Visit.

          -  General surgery within 1 month prior to the Screening Visit.

          -  Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease,
             amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic
             left ventricular aneurysm.

          -  Cerebrovascular accident or transient ischemic attack within 3 months prior to the
             Screening Visit.

          -  Liver enzyme (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST])
             elevation &gt;3x the upper limit of normal (ULN).

          -  Estimated glomerular filtration rate (eGFR) &lt;30 mL/min, using the Modification of Diet
             in Renal Disease (MDRD) Study equation.

          -  Known active drug or alcohol abuse.

          -  Active infection requiring systemic treatment or surgical intervention.

          -  Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise subject safety, limit the subject's ability to
             complete the study, and/or compromise the objectives of the study.

          -  Female patients who are pregnant or breastfeeding.

               -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Carr, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Stealth BioTherapeutics Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sotir Marchev, MD,PhD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bulgaria</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Bendavia™</keyword>
  <keyword>MTP-131</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

